Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2022.1113289 Oncology Correction Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient Wang Sha-Sha 1 † Wang Fang 2 † Zeng Zhen 1 Gao Fang 1 Liu Huan-Huan 3 Wang Hui-Na 3 Hu Yi 1 * Qin Hai-Feng 1 * 1 Department of Oncology, Chinese People’s Liberation Army General Hospital, Beijing, China 2 Department of Internal Medicine, OASIS International Hospital, Beijing, China 3 Department of Medicine, Acornmed Biotechnology Co., Ltd., Beijing, China

Edited and Reviewed by: Xianquan Zhan, Shandong First Medical University, China

*Correspondence: Hai-Feng Qin, hifo@263.net; Yi Hu, huyi301zlxb@sina.com

†These authors have contributed equally to this work

This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology

 13 12 2022 2022 12 1113289 01 12 2022 05 12 2022 Copyright © 2022 Wang, Wang, Zeng, Gao, Liu, Wang, Hu and Qin 2022 Wang, Wang, Zeng, Gao, Liu, Wang, Hu and Qin

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on: Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient. By Wang S-S, Wang F, Zeng Z, Gao F, Liu H-H, Wang H-N, Hu Y and Qin H-F (2022) Front. Oncol. 12:929763. doi: 10.3389/fonc.2022.929763 RET intergenic fusion pralsetinib lung adenocarcinoma novel intergenic tyrosine kinase inhibitors

In the published article, there were two errors made in the Case representation section regarding the dose of pralsetinib.

Firstly, a correction has been made to Case representation, Paragraph 1 on Page 2 of the article. The sentence “He was subsequently treated with pralsetinib (600 mg orally once daily)” has been corrected to “He was subsequently treated with pralsetinib (400 mg orally once daily)”.

Secondly, a correction has been made to Case representation, Paragraph 1 on Page 3. The sentence “Therefore, he was considered to achieve a partial response (PR) according to RECIST 1.1 criteria and continued to receive pralsetinib (600 mg orally once daily)” has been corrected to “Therefore, he was considered to achieve a partial response (PR) according to RECIST 1.1 criteria and continued to receive pralsetinib (400 mg orally once daily)”.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.